EP1157110A4 - Neutrokine-alpha and neutrokine-alpha splice variant - Google Patents

Neutrokine-alpha and neutrokine-alpha splice variant

Info

Publication number: EP1157110A4
Authority: EP; European Patent Office
Prior art keywords: neutrokine; alpha; splice variant; variant; alpha splice
Prior art date: 1999-02-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP00908739A

Other languages

German (de)

French (fr)

Other versions

EP1157110A1 (en

Inventor

Craig A Rosen

Jian Ni

Reinhard Ebner

Guo-Liang Yu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Human Genome Sciences Inc

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-23

Filing date

2000-02-22

Publication date

2006-05-10

1999-02-23 Priority claimed from US09/255,794 external-priority patent/US6716576B1/en

2000-02-22 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2000-02-22 Priority to EP07012741A priority Critical patent/EP1860190A3/en

2001-11-28 Publication of EP1157110A1 publication Critical patent/EP1157110A1/en

2006-05-10 Publication of EP1157110A4 publication Critical patent/EP1157110A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Oncology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Cell Biology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP00908739A 1999-02-23 2000-02-22 Neutrokine-alpha and neutrokine-alpha splice variant Withdrawn EP1157110A4 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP07012741A EP1860190A3 (en)	1999-02-23	2000-02-22	Neutrokine-alpha and neutrokine-alpha splice variants

Applications Claiming Priority (35)

Application Number	Priority Date	Filing Date	Title
US255794		1988-10-11
US09/255,794 US6716576B1 (en)	1996-10-25	1999-02-23	Method of assaying Neutrokine-α mRNA level
US12238899P	1999-03-02	1999-03-02
US122388P		1999-03-02
US12409799P	1999-03-12	1999-03-12
US124097P		1999-03-12
US12659999P	1999-03-26	1999-03-26
US126599P		1999-03-26
US12759899P	1999-04-02	1999-04-02
US127598P		1999-04-02
US13041299P	1999-04-16	1999-04-16
US130412P		1999-04-16
US13069699P	1999-04-23	1999-04-23
US130696P		1999-04-23
US13127899P	1999-04-27	1999-04-27
US131278P		1999-04-27
US13167399P	1999-04-29	1999-04-29
US131673P		1999-04-29
US13678499P	1999-05-28	1999-05-28
US136784P		1999-05-28
US14265999P	1999-07-06	1999-07-06
US142659P		1999-07-06
US14582499P	1999-07-27	1999-07-27
US145824P		1999-07-27
US16723999P	1999-11-24	1999-11-24
US167239P		1999-11-24
US16862499P	1999-12-03	1999-12-03
US168624P		1999-12-03
US17110899P	1999-12-16	1999-12-16
US171108P		1999-12-16
US17162699P	1999-12-23	1999-12-23
US17601500P	2000-01-14	2000-01-14
US176015P		2000-01-14
PCT/US2000/004336 WO2000050597A2 (en)	1999-02-23	2000-02-22	Neutrokine-alpha and neutrokine-alpha splice variant
US171626P		2009-04-22

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP07012741A Division EP1860190A3 (en)	1999-02-23	2000-02-22	Neutrokine-alpha and neutrokine-alpha splice variants

Publications (2)

Publication Number	Publication Date
EP1157110A1 EP1157110A1 (en)	2001-11-28
EP1157110A4 true EP1157110A4 (en)	2006-05-10

Family

ID=27586018

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP00908739A Withdrawn EP1157110A4 (en)	1999-02-23	2000-02-22	Neutrokine-alpha and neutrokine-alpha splice variant
EP07012741A Withdrawn EP1860190A3 (en)	1999-02-23	2000-02-22	Neutrokine-alpha and neutrokine-alpha splice variants

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP07012741A Withdrawn EP1860190A3 (en)	1999-02-23	2000-02-22	Neutrokine-alpha and neutrokine-alpha splice variants

Country Status (6)

Country	Link
EP (2)	EP1157110A4 (en)
JP (2)	JP2003526330A (en)
AU (2)	AU777536B2 (en)
CA (1)	CA2363112A1 (en)
NZ (2)	NZ513290A (en)
WO (1)	WO2000050597A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7217788B2 (en)	1996-03-14	2007-05-15	Human Genome Sciences, Inc.	Human tumor necrosis factor delta polypeptides
US6541224B2 (en)	1996-03-14	2003-04-01	Human Genome Sciences, Inc.	Tumor necrosis factor delta polypeptides
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US6689579B1 (en)	1996-10-25	2004-02-10	Human Genome Sciences, Inc.	Polynucleotides encoding neutrokine-α
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en)	1999-01-25	2003-05-22	Mackay Fabienne	BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
TR200102147T2 (en)	1999-01-25	2002-04-22	Biogen, Inc.	BAFF, associated blocking agents and their use in stimulation and inhibition of B-cells and immunoglobulins in response to immunity
EP1157110A4 (en) *	1999-02-23	2006-05-10	Human Genome Sciences Inc	Neutrokine-alpha and neutrokine-alpha splice variant
US6475987B1 (en)	1999-05-06	2002-11-05	National Jewish Medical And Research Center	Tall-1 receptor homologues
UA74798C2 (en)	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
AU3495301A (en)	2000-02-11	2001-08-20	Biogen Inc	Heterologous polypeptide of the tnf family
US6969519B2 (en)	2000-03-10	2005-11-29	Human Genome Sciences, Inc.	Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
KR101155294B1 (en)	2000-06-16	2013-03-07	캠브리지 안티바디 테크놀로지 리미티드	Antibodies that immunospecifically bind to BLyS
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en)	2000-06-16	2007-05-22	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2001288301A1 (en)	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
UA83458C2 (en)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
WO2002094192A2 (en)	2001-05-24	2002-11-28	Human Genome Sciences, Inc.	Antibodies against tumor necrosis factor delta (april)
AU2002309647C1 (en)	2001-05-25	2008-09-11	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to trail receptors
AR035119A1 (en)	2001-08-16	2004-04-14	Lilly Co Eli	ANTI-HTNFSF13B HUMAN ANTI-BODIES
EP1608730B1 (en)	2003-03-28	2013-11-06	Biogen Idec MA Inc.	Truncated baff receptors
EP1855724A2 (en) *	2005-02-01	2007-11-21	Research Development Foundation	Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
EP1922079A2 (en)	2005-08-09	2008-05-21	ZymoGenetics, Inc.	Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
KR20080056714A (en)	2005-08-09	2008-06-23	지모제넥틱스, 인코포레이티드	Methods for treating b-cell malignancies using taci-ig fusion molecule
JP5905184B2 (en)	2005-10-13	2016-04-20	ヒューマンジノームサイエンシーズ，インコーポレイテッドＨｕｍａｎＧｅｎｏｍｅＳｃｉｅｎｃｅｓ，Ｉｎｃ．	Methods and compositions for use in treating patients with autoantibody positive disease
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
JP6088723B2 (en)	2005-11-23	2017-03-01	ジェネンテック，インコーポレイテッド	Compositions and methods for B cell assays.
US8211649B2 (en)	2006-03-31	2012-07-03	Human Genome Sciences, Inc.	Methods of diagnosing and prognosing hodgkin's lymphoma
BRPI0711823A2 (en)	2006-05-15	2012-01-17	Ares Trading Sa	methods for treating autoimmune diseases with a taci-ig fusion molecule
US20080233132A1 (en) *	2006-11-03	2008-09-25	Miller Stephen D	Multiple sclerosis therapy
JP2010534652A (en) *	2007-07-26	2010-11-11	イプセンファルマソシエテパアクシオンスシンプリフィエ	Chemokine analog

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998018921A1 (en) *	1996-10-25	1998-05-07	Human Genome Sciences, Inc.	NEUTROKINE $g(a)
WO2000050597A2 (en) *	1999-02-23	2000-08-31	Human Genome Sciences, Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
US6403770B1 (en) *	1996-10-25	2002-06-11	Human Genome Sciences, Inc.	Antibodies to neutrokine-alpha

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998027114A2 (en) *	1996-12-17	1998-06-25	Schering Corporation	Mammalian cell surface antigens; related reagents
CA2232743A1 (en) *	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
JP2001515711A (en) *	1997-09-12	2001-09-25	バイオジェンインコーポレイテッド	Kay-a novel immune system protein
WO1999033980A2 (en) *	1997-12-30	1999-07-08	Chiron Corporation	Members of tnf and tnfr families

2000
- 2000-02-22 EP EP00908739A patent/EP1157110A4/en not_active Withdrawn
- 2000-02-22 WO PCT/US2000/004336 patent/WO2000050597A2/en not_active Application Discontinuation
- 2000-02-22 JP JP2000601161A patent/JP2003526330A/en active Pending
- 2000-02-22 AU AU30028/00A patent/AU777536B2/en not_active Expired
- 2000-02-22 NZ NZ513290A patent/NZ513290A/en not_active IP Right Cessation
- 2000-02-22 CA CA002363112A patent/CA2363112A1/en not_active Abandoned
- 2000-02-22 EP EP07012741A patent/EP1860190A3/en not_active Withdrawn
2003
- 2003-11-14 NZ NZ529555A patent/NZ529555A/en not_active IP Right Cessation
2005
- 2005-01-20 AU AU2005200237A patent/AU2005200237B2/en not_active Expired
2007
- 2007-04-19 JP JP2007111070A patent/JP2007277249A/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998018921A1 (en) *	1996-10-25	1998-05-07	Human Genome Sciences, Inc.	NEUTROKINE $g(a)
US6403770B1 (en) *	1996-10-25	2002-06-11	Human Genome Sciences, Inc.	Antibodies to neutrokine-alpha
WO2000050597A2 (en) *	1999-02-23	2000-08-31	Human Genome Sciences, Inc.	Neutrokine-alpha and neutrokine-alpha splice variant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200053, Derwent World Patents Index; Class B04, AN 2000-572093, XP002331367 *

Also Published As

Publication number	Publication date
JP2003526330A (en)	2003-09-09
NZ529555A (en)	2005-09-30
EP1157110A1 (en)	2001-11-28
AU777536B2 (en)	2004-10-21
AU3002800A (en)	2000-09-14
EP1860190A2 (en)	2007-11-28
JP2007277249A (en)	2007-10-25
EP1860190A3 (en)	2008-03-12
NZ513290A (en)	2004-05-28
CA2363112A1 (en)	2000-08-31
AU2005200237B2 (en)	2007-11-29
AU2005200237A1 (en)	2005-02-17
WO2000050597A2 (en)	2000-08-31

Publication	Publication Date	Title
EP1157110A4 (en)	2006-05-10	Neutrokine-alpha and neutrokine-alpha splice variant
HRP20060251B1 (en)	2016-08-12	Substituted oxasolidinones and their use
EP1309718A4 (en)	2004-08-25	Neutrokine-alpha and neutrokine-alpha splice variant
AU3620600A (en)	2000-09-28	Skin-marking devices and their use
GB9712347D0 (en)	1997-08-13	Vaccine
GB9711990D0 (en)	1997-08-06	Vaccine
EP1507793A4 (en)	2006-02-01	Neutrokine-alpha and neutrokine-alpha splice variant
GB2350631B (en)	2003-11-19	Combination whipstock and anchor
HUP0203896A3 (en)	2003-05-28	Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
GB2352523B (en)	2003-07-09	Fluid-gauging systems and methods
GB0023323D0 (en)	2000-11-08	Arylhydantoin derivatives and uses thereof
EP1194147A4 (en)	2002-10-09	Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9704349D0 (en)	1997-04-23	Levobupivacaine and its use
TW424891U (en)	2001-03-01	Holding and fixing structure
NO991348L (en)	1999-05-21	Oljebr ° When ° r
EP1229913A4 (en)	2005-01-19	Substituted 1-benzazepines and derivatives thereof
IL129907A0 (en)	2000-02-29	Alternative splice variants
GB0021915D0 (en)	2000-10-25	Creating and managing E-receipts
AU2669201A (en)	2001-06-12	Taccalonolides and their use
GB9704370D0 (en)	1997-04-23	Levobupivacaine and its use
HK1046707A1 (en)	2003-01-24	Neutrokine-alpha and neutrokine-alpha splice variant
GB9929581D0 (en)	2000-02-09	Comjpositions and their use
GB2354395B (en)	2004-01-21	Telephone system and circuitry
GB2389158B (en)	2004-02-18	Anchorage
GB9722023D0 (en)	1997-12-17	Levobupivacaine and its use

Legal Events

Date	Code	Title	Description
2001-10-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2001-11-28	17P	Request for examination filed	Effective date: 20010924
2001-11-28	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2001-11-28	AX	Request for extension of the european patent	Free format text: AL;LT;LV;MK;RO;SI
2006-05-10	A4	Supplementary search report drawn up and despatched	Effective date: 20060328
2007-01-17	17Q	First examination report despatched	Effective date: 20061219
2007-11-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2007-12-19	18D	Application deemed to be withdrawn	Effective date: 20070630
2008-10-03	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1046707 Country of ref document: HK